Dr. Kurkjian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4401 McAuley Blvd
Ste 2700
Oklahoma City, OK 73120Phone+1 405-751-4343Fax+1 405-751-4346
Education & Training
- University of Oklahoma Health Sciences CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
- University of Oklahoma College of MedicineClass of 2001
Certifications & Licensure
- CA State Medical License 2009 - Present
- OK State Medical License 2002 - 2025
- TX State Medical License 2014 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
- Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 61 citationsA first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancerShubham Pant, Suzanne F. Jones, Carla Kurkjian, Jeffrey R. Infante, Kathleen N. Moore
European Journal of Cancer. 2016-03-01 - 35 citationsA phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients...Carol Aghajanian, Katherine M. Bell-McGuinn, Howard A. Burris, Lillian L. Siu, Lee Ann Stayner
Investigational New Drugs. 2018-04-03 - 35 citationsTAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignanciesHoward A. Burris, Carla Kurkjian, Lowell L. Hart, Shubham Pant, Patrick Murphy
Cancer Chemotherapy and Pharmacology. 2017-06-10
Press Mentions
- Former Volunteer Joins Mercy as Vice President of Cancer Services in OklahomaOctober 4th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: